Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab

Choong kun Lee, Seung seob Kim, Saemi Park, Chan Kim, Su Jin Heo, Joon Seok Lim, Hyunki Kim, Hyo Song Kim, Sun Young Rha, Hyun Cheol Chung, Sohee Park, Minkyu Jung

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: We aimed to determine and compare the predictive values of depth of response (DpR) and early tumor shrinkage (ETS) on long-term outcomes in gastric cancer patients treated with trastuzumab. Results: From a total of 368 computed tomography examinations, DpR and ETS were evaluated. DpR was a significant tumor-size metric in predicting PFS and OS, and showed better discriminatory ability (higher Ct indices, 0.6957 for PFS; 0.7191 for OS) than ETS. DpR ≥ 45% (vs. < 45%) was the optimal cutoffvalue, as it was best able to identify patients with longer PFS (median 9.0 vs. 6.3 months, hazard ratio [HR] = 0.608; 95% confidence interval [CI]: 0.335 to 1.104; P = 0.102) and OS (median 23.5 vs. 13.1 months, HR = 0.441; 95% CI: 0.203 to 0.955; P = 0.038). Materials and Methods: Sixty-one gastric cancer patients who received first-line trastuzumab-based chemotherapy were assessed for DpR and ETS. We employed Kaplan-Meier estimates, log-rank tests, Cox proportional hazards regression models, time-dependent receiver operating characteristics, and Youden's J index to evaluate and determine cutoffvalues of DpR and ETS as predictors of progression-free survival (PFS) and overall survival (OS). Conclusions: DpR and ETS were significant predictors of long-term outcomes in gastric cancer patients treated with first-line trastuzumab. Validation in prospective trials with larger patient populations is needed.

Original languageEnglish
Pages (from-to)31169-31179
Number of pages11
JournalOncotarget
Volume8
Issue number19
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Stomach Neoplasms
Disease-Free Survival
Neoplasms
Survival
Confidence Intervals
Kaplan-Meier Estimate
Trastuzumab
Proportional Hazards Models
ROC Curve
Tomography
Drug Therapy
Population

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Lee, Choong kun ; Kim, Seung seob ; Park, Saemi ; Kim, Chan ; Heo, Su Jin ; Lim, Joon Seok ; Kim, Hyunki ; Kim, Hyo Song ; Rha, Sun Young ; Chung, Hyun Cheol ; Park, Sohee ; Jung, Minkyu. / Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. In: Oncotarget. 2017 ; Vol. 8, No. 19. pp. 31169-31179.
@article{621314e2d4954051aa8f627969f8fe55,
title = "Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab",
abstract = "Purpose: We aimed to determine and compare the predictive values of depth of response (DpR) and early tumor shrinkage (ETS) on long-term outcomes in gastric cancer patients treated with trastuzumab. Results: From a total of 368 computed tomography examinations, DpR and ETS were evaluated. DpR was a significant tumor-size metric in predicting PFS and OS, and showed better discriminatory ability (higher Ct indices, 0.6957 for PFS; 0.7191 for OS) than ETS. DpR ≥ 45{\%} (vs. < 45{\%}) was the optimal cutoffvalue, as it was best able to identify patients with longer PFS (median 9.0 vs. 6.3 months, hazard ratio [HR] = 0.608; 95{\%} confidence interval [CI]: 0.335 to 1.104; P = 0.102) and OS (median 23.5 vs. 13.1 months, HR = 0.441; 95{\%} CI: 0.203 to 0.955; P = 0.038). Materials and Methods: Sixty-one gastric cancer patients who received first-line trastuzumab-based chemotherapy were assessed for DpR and ETS. We employed Kaplan-Meier estimates, log-rank tests, Cox proportional hazards regression models, time-dependent receiver operating characteristics, and Youden's J index to evaluate and determine cutoffvalues of DpR and ETS as predictors of progression-free survival (PFS) and overall survival (OS). Conclusions: DpR and ETS were significant predictors of long-term outcomes in gastric cancer patients treated with first-line trastuzumab. Validation in prospective trials with larger patient populations is needed.",
author = "Lee, {Choong kun} and Kim, {Seung seob} and Saemi Park and Chan Kim and Heo, {Su Jin} and Lim, {Joon Seok} and Hyunki Kim and Kim, {Hyo Song} and Rha, {Sun Young} and Chung, {Hyun Cheol} and Sohee Park and Minkyu Jung",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.16099",
language = "English",
volume = "8",
pages = "31169--31179",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "19",

}

Lee, CK, Kim, SS, Park, S, Kim, C, Heo, SJ, Lim, JS, Kim, H, Kim, HS, Rha, SY, Chung, HC, Park, S & Jung, M 2017, 'Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab', Oncotarget, vol. 8, no. 19, pp. 31169-31179. https://doi.org/10.18632/oncotarget.16099

Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. / Lee, Choong kun; Kim, Seung seob; Park, Saemi; Kim, Chan; Heo, Su Jin; Lim, Joon Seok; Kim, Hyunki; Kim, Hyo Song; Rha, Sun Young; Chung, Hyun Cheol; Park, Sohee; Jung, Minkyu.

In: Oncotarget, Vol. 8, No. 19, 01.01.2017, p. 31169-31179.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab

AU - Lee, Choong kun

AU - Kim, Seung seob

AU - Park, Saemi

AU - Kim, Chan

AU - Heo, Su Jin

AU - Lim, Joon Seok

AU - Kim, Hyunki

AU - Kim, Hyo Song

AU - Rha, Sun Young

AU - Chung, Hyun Cheol

AU - Park, Sohee

AU - Jung, Minkyu

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose: We aimed to determine and compare the predictive values of depth of response (DpR) and early tumor shrinkage (ETS) on long-term outcomes in gastric cancer patients treated with trastuzumab. Results: From a total of 368 computed tomography examinations, DpR and ETS were evaluated. DpR was a significant tumor-size metric in predicting PFS and OS, and showed better discriminatory ability (higher Ct indices, 0.6957 for PFS; 0.7191 for OS) than ETS. DpR ≥ 45% (vs. < 45%) was the optimal cutoffvalue, as it was best able to identify patients with longer PFS (median 9.0 vs. 6.3 months, hazard ratio [HR] = 0.608; 95% confidence interval [CI]: 0.335 to 1.104; P = 0.102) and OS (median 23.5 vs. 13.1 months, HR = 0.441; 95% CI: 0.203 to 0.955; P = 0.038). Materials and Methods: Sixty-one gastric cancer patients who received first-line trastuzumab-based chemotherapy were assessed for DpR and ETS. We employed Kaplan-Meier estimates, log-rank tests, Cox proportional hazards regression models, time-dependent receiver operating characteristics, and Youden's J index to evaluate and determine cutoffvalues of DpR and ETS as predictors of progression-free survival (PFS) and overall survival (OS). Conclusions: DpR and ETS were significant predictors of long-term outcomes in gastric cancer patients treated with first-line trastuzumab. Validation in prospective trials with larger patient populations is needed.

AB - Purpose: We aimed to determine and compare the predictive values of depth of response (DpR) and early tumor shrinkage (ETS) on long-term outcomes in gastric cancer patients treated with trastuzumab. Results: From a total of 368 computed tomography examinations, DpR and ETS were evaluated. DpR was a significant tumor-size metric in predicting PFS and OS, and showed better discriminatory ability (higher Ct indices, 0.6957 for PFS; 0.7191 for OS) than ETS. DpR ≥ 45% (vs. < 45%) was the optimal cutoffvalue, as it was best able to identify patients with longer PFS (median 9.0 vs. 6.3 months, hazard ratio [HR] = 0.608; 95% confidence interval [CI]: 0.335 to 1.104; P = 0.102) and OS (median 23.5 vs. 13.1 months, HR = 0.441; 95% CI: 0.203 to 0.955; P = 0.038). Materials and Methods: Sixty-one gastric cancer patients who received first-line trastuzumab-based chemotherapy were assessed for DpR and ETS. We employed Kaplan-Meier estimates, log-rank tests, Cox proportional hazards regression models, time-dependent receiver operating characteristics, and Youden's J index to evaluate and determine cutoffvalues of DpR and ETS as predictors of progression-free survival (PFS) and overall survival (OS). Conclusions: DpR and ETS were significant predictors of long-term outcomes in gastric cancer patients treated with first-line trastuzumab. Validation in prospective trials with larger patient populations is needed.

UR - http://www.scopus.com/inward/record.url?scp=85019137821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019137821&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.16099

DO - 10.18632/oncotarget.16099

M3 - Article

AN - SCOPUS:85019137821

VL - 8

SP - 31169

EP - 31179

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 19

ER -